![]() ![]() ![]() ![]() ![]() |
![]() |
![]() |
![]() |
||
---|---|---|---|
ParAllele Press Release
Read/Download the PDF
AFFYMETRIX TO SUPPLY PARALLELE BIOSCIENCE WITH GENECHIP® TAG ARRAYSSanta Clara, Calif. and South San Francisco, Calif., March 18, 2003 - Affymetrix, Inc., (NASDAQ: AFFX) and ParAllele Bioscience today announced an agreement under which Affymetrix will supply ParAllele with GeneChip(R) Tag Arrays for use in combination with ParAllele's proprietary "lab in a tube"(TM) assay technology for custom single nucleotide polymorphism (SNP) genotyping.Under the terms of the three-year, non-exclusive agreement, Affymetrix will supply catalog and custom-designed tag arrays to ParAllele for use in its commercial genotyping service business, and with its pharmaceutical collaborators. The companies also entered into a research and development agreement in which ParAllele will use Affymetrix' GeneChip(R) Brand Tag Arrays to develop a range of SNP assays that ParAllele will make available to its customers. Financial terms of the agreement were not disclosed. Affymetrix GeneChip(R) Tag Arrays are universal detection devices that can be utilized with a number of different assays. Each array contains sets of unique "tag" sequences that hybridize to complementary sequences generated in the assay. ParAllele's Molecular Inversion Probe (MIP) assay technology allows up to 10,000 genotyping reactions to be combined in a single tube. Together, these technologies provide a scalable and flexible genotyping solution for a wide variety of DNA analysis applications, including fine mapping and custom SNP genotyping. "Affymetrix has introduced innovative new products for DNA analysis -- the GeneChip Human Mapping 10K Array for whole genome mapping and the GeneChip CustomSeq(TM) Array Program for resequencing," said Greg Yap, Affymetrix' Senior Marketing Director, DNA Analysis. "In addition, we look forward to supplying our Tag Arrays to ParAllele to enable them to provide services to customers such as refining linkage regions or undertaking candidate gene studies." "ParAllele is now positioned to deliver a wide range of SNP discovery and genotyping solutions," said Tom Willis, Ph.D., Chief Executive Officer of ParAllele. "This agreement ensures us access to a high-quality, high-content microarray platform and allows ParAllele to focus on its reagents and collaborations-based business model. We have been using Affymetrix GeneChip Tag Arrays in our collaboration with Baylor University on the NIH-funded International HapMap Project and we are very pleased with the results." About Affymetrix About ParAllele BioscienceParAllele BioScience is developing and commercializing new products and technologies that will accelerate healthcare breakthroughs. By harnessing biochemical processes, ParAllele is creating highly multiplexed, compact, scalable solutions for genetics research. The company's current offerings include solutions for SNP discovery, genotyping, and variation scanning. ParAllele's customers and partners include leading pharmaceutical companies, academic research centers, life science instrumentation companies and the National Institutes of Health (NIH). The company was founded by a team of researchers from the Stanford Genome Technology Center and Uppsala University in 2001 and is presently headquartered in South San Francisco, California. Investors in the privately held company include Abingworth Management, Index Ventures, Mohr Davidow Ventures (MDV) and Versant Ventures. For more information about ParAllele, please visit the company's website at: parallelebio.com. |
|||
All site contents Copyright © 2001-2004 ParAllele BioScience, Inc. All rights reserved. |